Jonathan Bennett

Dr. Jonathan Bennett

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
JBJonathan Bennett
Jonathan Bennett
GTGeorge D. Thornton
George D. Thornton
CNChristian Nitsche
Christian Nitsche
FGFrancisco Gama
Francisco Gama
NANikoo Aziminia
Nikoo Aziminia
JYJohn Yap
John Yap
BACKGROUND: In aortic stenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. Following aortic valve replacement (AVR), left ventricular hypertrophy regression occurs, but early cellular and extracellular dynamics are unknown. METHODS: Patients with severe symptomatic aortic stenosis undergoing surgical or transcatheter AVR were prospectively recruited. Pre- and early post-AVR cardiac magnetic resonance imaging assessed left ventricular remodeling, global longitudinal strain, and T1 mapping to determine extracellular volume fraction and volume of cellular and extracellular compartments. RESULTS: In all, 39 patients (aged 71.4±9.8 years, male 79%, aortic valve peak velocity 4.4±0.5 m/s) underwent cardiac magnetic resonance before and at median 7.7 weeks post-AVR. Left ventricular mass index reduced significantly by 15.4% ( P <0.001*), primarily driven by cellular compartment regression (18.7%, P <0.001*), with a smaller reduction in the extracellular compartment (7.2%, P <0.001*). This unbalanced regression led to an apparent increase in extracellular volume fraction (27.4±3.1% to 30.2±2.8%; P 0.05). The asterisk in P values indicates a statistical significance of <0.05. CONCLUSIONS: Within 8 weeks of AVR for aortic stenosis, substantial left ventricular hypertrophy regression occurs involving both cellular and extracellular compartments, demonstrating the early myocardial adaptability to afterload relief. Cellular compartment regression is greater than extracellular regression, leading to an apparent increase in extracellular volume fraction. Mode of intervention did not affect degree of reverse remodeling, indicating that both are effective at resulting beneficial changes post-AVR. REGISTRATION: URL: https://www.isrctn.com ; Unique identifier: NCT04627987.

16 January 2023 in Cerebrovascular Diseases Extra
Verified
Journal Article
Open access
PDF file
MDMadu van Dinther
Madu van Dinther
JBJonathan Bennett
Jonathan Bennett
GTGeorge D. Thornton
George D. Thornton
PVPaulien Voorter
Paulien Voorter
ACAna Ezponda Casajús
Ana Ezponda Casajús
TTThomas Alexander Treibel
Thomas Alexander Treibel
Introduction: Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysiology of small blood vessel-related disorders including vascular cognitive impairment (VCI) due to cerebral small vessel disease and heart failure with preserved ejection fraction (HFpEF). Both diseases share common risk factors including hypertension, diabetes mellitus, obesity, and ageing; in turn, these comorbidities are associated with microvascular rarefaction. Our consortium aims to investigate novel non-invasive tools to quantify microvascular health and rarefaction in both organs, as well as surrogate biomarkers for cerebral and/or cardiac rarefaction (via sublingual capillary health, vascular density of the retina, and RNA content of circulating extracellular vesicles), and to determine whether microvascular density relates to disease severity. Methods: The clinical research program of CRUCIAL consists of four observational cohort studies. We aim to recruit 75 VCI patients, 60 HFpEF patients, 60 patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement as a pressure overload HFpEF model, and 200 elderly participants with mixed comorbidities to serve as controls. Data collected will include medical history, physical examination, cognitive testing, advanced brain and cardiac MRI, ECG, echocardiography, sublingual capillary health, optical coherence tomography angiography (OCTa), extracellular vesicles RNA analysis, and myocardial remodelling-related serum biomarkers. The AS cohort undergoing surgery will also have myocardial biopsy for histological microvascular assessment. Discussion: CRUCIAL will examine the pathophysiological role of microvascular rarefaction in VCI and HFpEF using advanced brain and cardiac MRI techniques. Furthermore, we will investigate surrogate biomarkers for non-invasive, faster, easier, and cheaper assessment of microvascular density since these are more likely to be disseminated into widespread clinical practice. If microvascular rarefaction is an early marker of developing small vessel diseases, then measuring rarefaction may allow preclinical diagnosis, with implications for screening, risk stratification, and prevention. Further knowledge of the relevance of microvascular rarefaction and its underlying mechanisms may provide new avenues for research and therapeutic targets.

4 March 2023 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Open access
NANikoo Aziminia
Nikoo Aziminia
CNChristian Nitsche
Christian Nitsche
RMRok Mravljak
Rok Mravljak
JBJonathan Bennett
Jonathan Bennett
GTGeorge D Thornton
George D Thornton
TTThomas A Treibel
Thomas A Treibel
In aortic stenosis (AS), the heart transitions from adaptive compensation to an AS cardiomyopathy and eventually leads to decompensation with heart failure. Better understanding of the underpinning...

5 September 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
GTGeorge D Thornton
George D Thornton
MMMichael McKenna
Michael McKenna
JBJonathan Bennett
Jonathan Bennett
AHAlun D. Hughes
Alun D. Hughes
AGArantxa González
Arantxa González
TTThomas A Treibel
Thomas A Treibel
Current guideline criteria for surgical intervention in chronic aortic regurgitation (AR) rely on fixed thresholds of left ventricular size and ejection fraction, but these metrics may overlook early myocardial injury and under-appreciate patient heterogeneity, particularly in women and older adults. Cardiovascular magnetic resonance (CMR) offers robust quantification of regurgitant volume, three-dimensional ventricular volumes, and both focal (late gadolinium enhancement) and diffuse (T1-mapping–derived extracellular volume) fibrosis. Observational studies have linked CMR-detected fibrosis to worse clinical outcomes and less favourable reverse remodelling after valve intervention, suggesting that fibrosis may mark the transition from compensated overload to irreversible myocardial damage. In this narrative review, we appraise the limitations of current guidelines, compare echocardiographic and CMR approaches to AR assessment, and summarize the evidence supporting myocardial fibrosis as a potential imaging biomarker for risk stratification. We discuss how integrating CMR-derived fibrosis metrics with volumetric and functional data could personalize timing of aortic valve intervention. While prospective studies are needed to validate fibrosis-guided decision-making, this evolving paradigm holds promise for earlier identification of patients at risk for irreversible myocardial injury, with the ultimate goal of preserving ventricular function and improving long-term outcomes.

4 September 2023 in Medicina
Verified
Journal Article
Open access
PDF file
JBJonathan Bennett
Jonathan Bennett
MDMadu van Dinther
Madu van Dinther
PVPaulien Voorter
Paulien Voorter
WBWalter Backes
Walter Backes
JBJosephine Barnes
Josephine Barnes
TTThomas A Treibel
Thomas A Treibel
The objective of this review is to investigate the commonalities of microvascular (small vessel) disease in heart failure with preserved ejection fraction (HFpEF) and cerebral small vessel disease (CSVD). Furthermore, the review aims to evaluate the current magnetic resonance imaging (MRI) diagnostic techniques for both conditions. By comparing the two conditions, this review seeks to identify potential opportunities to improve the understanding of both HFpEF and CSVD.

1 June 2019 in Heart
Verified
Journal Article
Closed access
PDF file
JBJonathan Bennett
Jonathan Bennett
RSRupert Simpson
Rupert Simpson